Wednesday, July 8, 2026

Drug profile · INN

flavoxate hydrochloride

flavoxate hydrochloride (FLAVOXATE HYDROCHLORIDE) is a phosphodiesterase 4 inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — flavoxate hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

flavoxate hydrochloride (FLAVOXATE HYDROCHLORIDE) is a phosphodiesterase 4 inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN flavoxate hydrochloride
Brand FLAVOXATE HYDROCHLORIDE
Mechanism Phosphodiesterase 4 inhibitor
Target Phosphodiesterase 4
Route ORAL
Formulation TABLET

Mechanism of action

Phosphodiesterase 4 inhibitor

Primary target: Phosphodiesterase 4

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. apremilast Antineoplastic and immunomodulating agents (L04)
  2. roflumilast Respiratory system (R03)
  3. amlexanox Phosphodiesterase 4 inhibitor
  4. crisaborole Dermatologicals (D11)
  5. difamilast Phosphodiesterase 4 inhibitor

Frequently asked questions

What is flavoxate hydrochloride?

flavoxate hydrochloride (FLAVOXATE HYDROCHLORIDE) is a phosphodiesterase 4 inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for flavoxate hydrochloride?

FLAVOXATE HYDROCHLORIDE is a marketed brand name for flavoxate hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of flavoxate hydrochloride?

flavoxate hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.